Evidence map›Paper›PMID 32845933›Full record

ArticlePloS one2020

HIV serologically indeterminate individuals: Future HIV status and risk factors.

George Mwinnyaa, Mary K Grabowski, Ronald H Gray, Maria Wawer, Larry W Chang, Joseph Ssekasanvu, Joseph Kagaayi, Godfrey Kigozi, Sarah Kalibbala, Ronald M Galiwango and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

George MwinnyaaNIAID, Baltimore, MD, United States of America.ORCID 0000-0002-1924-6065
Mary K GrabowskiJohns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Ronald H GrayJohns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States of America.
Maria WawerJohns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States of America.
Larry W ChangJohns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Joseph SsekasanvuJohns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States of America.
Joseph KagaayiRakai Health Sciences Program, Kalisizo, Uganda.
Godfrey KigoziRakai Health Sciences Program, Kalisizo, Uganda.
Sarah KalibbalaRakai Health Sciences Program, Kalisizo, Uganda.
Ronald M GaliwangoRakai Health Sciences Program, Kalisizo, Uganda.
Anthony NdyanaboRakai Health Sciences Program, Kalisizo, Uganda.
David SerwaddaMakerere University, Kampala, Uganda.
Thomas C QuinnNIAID, Baltimore, MD, United States of America.
Steven J ReynoldsNIAID, Baltimore, MD, United States of America.
Oliver LaeyendeckerNIAID, Baltimore, MD, United States of America.
Johns Hopkins University · USRakai Health Sciences Program · UGActionAid · USMakerere University · UG

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Circumcision: HIV/STIs and behaviors in a RCT and post-RCT surveillance; RakaiU01AI075115 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2007 to 2011
$9.3M
ARV effects on HIV epidemiology &behaviors Rakai UgandaR01HD050180 · NICHD · JOHNS HOPKINS UNIVERSITY · PI WAWER, MARIA J · 2005 to 2009
$7.8M
Methods for Reducing Spatial Uncertainty and Bias in Disease SurveillanceR01AI102939 · NIAID · JOHNS HOPKINS UNIVERSITY · PI LESSLER, JUSTIN · 2013 to 2017
$4.6M
Enhanced Provision of Male Circumcision for HIV Prevention, Rakai, UgandaU01AI100031 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2012 to 2014
$3.2M
CHWs, mHealth, and Combination HIV Prevention in a Hotspot: A Randomized TrialR01MH107275 · NIMH · JOHNS HOPKINS UNIVERSITY · PI CHANG, LARRY WILLIAM · 2015 to 2019
$2.7M
HIV Incidence, Transmission Dynamics and Combination HIV Prevention: Rakai UgandaR01AI110324 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRAY, RONALD H · 2014 to 2016
$2.4M
The Problem With Male Sexual/Repro Health:Qualitative/Quantitative Study, UgandaR01HD070769 · NICHD · JOHNS HOPKINS UNIVERSITY · PI WAWER, MARIA J · 2011 to 2013
$1.4M
Revealing women's hidden role as critical components of HIV transmission networks in Rakai, Uganda: an interdisciplinary approachK01AI125086 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GRABOWSKI, MARY KATHRYN · 2016 to 2020
$638k
NIAID NIH HHS K01 AI125086NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI102939NIAID NIH HHS R01 AI110324NIAID NIH HHS U01 AI075115NIAID NIH HHS U01 AI100031NICHD NIH HHS R01 HD050180NICHD NIH HHS R01 HD070769NIMH NIH HHS R01 MH107275
6 · The paper itself

Abstract

backgroundIndeterminate HIV test results are common, but little is known about the evolution of indeterminate serology and its sociodemographic and behavioral correlates. We assessed future HIV serological outcomes for individuals with indeterminate results and associated factors in Rakai, Uganda.

methods115,944 serological results, defined by two enzyme immunoassay (EIAs), among 39,440 individuals aged 15-49 years in the Rakai Community Cohort Study were assessed. Indeterminate results were defined as contradictory EIAs. Modified Poisson regression models with generalized estimating equations were used to assess prevalence ratios (PRs) of subsequent HIV serological outcomes and factors associated with HIV indeterminate results.

resultsThe prevalence of HIV serologically indeterminate results was 4.9%. Indeterminate results were less likely among women than men (adjPR 0.76, 95% CI 0.71,0.81), in unmarried participants than married participants (adjPR 0.92, 95% CI 0.85,99), and in individuals with primary (adjPR 0.90, 95% CI 0.80,1.02), secondary (adjPR 0.83, 95% CI 0.73,0.96) and post-secondary (adjPR 0.75, 95% CI 0.60,0.94) education, relative to no education. The proportions of persons with indeterminate results progressing to HIV positive, negative or indeterminate results in subsequent visits was 5%, 71% and 24%, respectively.

conclusionHIV serologically indeterminate results were associated with gender and marital status. HIV surveillance programs should develop a protocol for reporting individuals with mixed or persistently indeterminate HIV results on multiple follow-up visits. Most indeterminate results became HIV-negative over time, but follow-up is still needed to detect positive serologies.

Indexed as

AdolescentAdultAIDS SerodiagnosisFemaleFollow-Up StudiesHIVHIV InfectionsHumansLongitudinal StudiesMaleMarriageMiddle AgedPrevalenceRisk FactorsUgandaYoung Adult

Identifiers

PMID32845933
PMCPMC7449388
OpenAlexW3081486249

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.